Niacin-Time 500 mg

Niacin-Time 500 mg

Carlson4.7 (121 ratings)
Format:Tablet Quantity: 100 Tablet(s) · 100 servings
Goals
$23.38 $0.23 per serving
Pure FormulasLowest$23.38iHerb$23.38

About this product

The formula provides nicotinic acid in a time-release product, giving it a more specific purpose than generic vitamin B3. The disclosed amount is substantial and not intended merely to meet daily nutrient needs.

Slower release may reduce the intensity of an immediate flush for some users. It does not remove systemic risks and can make liver monitoring especially relevant during regular use.

The best fit is a professionally guided lipid-focused plan. Skin support does not require this aggressive amount, and casual self-use offers an unfavorable risk-to-need balance.

Who is it for
  • Adults using high-dose nicotinic acid under supervision
  • People who prefer time-release delivery
  • Users with a defined cardiovascular plan
Best for
  • Professionally guided nicotinic acid use
  • Time-release dosing
  • Lipid-focused supplementation

Pros

  • Clearly names nicotinic acid
  • Time-release format
  • Focused single-ingredient formula

Cons

  • Too strong for basic nutrition
  • Requires monitoring during regular use
  • Skin goal does not justify the dose

Warnings

  • Time-release nicotinic acid may affect liver enzymes, especially with sustained high-dose use.
  • The amount can raise glucose or uric acid and matters for diabetes or gout.
  • Flushing, dizziness, or stomach upset may still occur despite slower release.

Product analysis

78 out of 100
A high-dose time-release nicotinic acid formula suited to supervised cardiovascular use. The release design does not eliminate liver or metabolic concerns.

AI assessment of the formula, label and price. How scoring works

Nutrient quality85

Sustained-release nicotinic acid provides a purposeful cardiovascular niacin form. The amount is meaningful for targeted cardiovascular use.

.
Ingredient transparency84

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.
Customer satisfaction64

The aggregate satisfaction measure is strong, but the small evidence base limits confidence. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.
Value for money76

The price is only partly justified by the formula quality and dose. Each serving provides only moderate cost efficiency.

.
Format
Tablet
Container
100 Tablet(s)
Per serving
$0.23
Customer rating
4.7 · 121 ratings
Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
High effect
A+ Ingredient FitD+ PathwaysB- EvidenceA+ Formulation Logic
Niacin · 500 mg

Niacin-Time 500 mg is a focused single-ingredient product with 500 mg of nicotinic acid per serving. Its coverage concentrates on triglyceride handling, while other cardiovascular pathways are not represented. Studies include the nicotinic acid preparation at a relevant amount, but niacin's evidence is below the strongest represented for this goal.

How this product is rated for Cardiovascular Support

Ingredient fit96

Nicotinic acid is the sole goal-linked ingredient, with a clear serving amount and no off-goal actives.
Goal fit
Niacin is the only credited active, and no off-goal actives are listed.
Dose adequacy
The declared 500 mg serving amount is high enough for niacin to contribute toward this goal.

Pathways53

The formula's coverage centers on triglyceride handling; other cardiovascular pathways are not represented.
Depth
Triglyceride handling has the strongest pathway coverage.
Breadth
Coverage appears only in triglyceride handling; other target pathways are unrepresented.

Evidence74

Studies include the nicotinic acid preparation at a relevant amount, though niacin's evidence is below the strongest represented for this goal.
Evidence strength
Niacin has the strongest evidence among ingredients at goal-relevant amounts, but the goal includes stronger evidence.
Studied preparation
Studies used the nicotinic acid preparation at an amount relevant to this goal.

Formulation logic100

The single active is present at an amount relevant to this goal, needs no missing partner, and has no matched conflict.
Partner coverage
Niacin works without another credited ingredient.
Conflicts
No matched ingredient conflict is recorded.
Effective doses
The niacin amount is high enough to contribute toward this goal.
Study evidence
Niacin Supportive 136 studies
Heart Health
Lipid and Cholesterol Balance
Heart Health
Impact
Moderate effect
A+ Ingredient FitF PathwaysC EvidenceA+ Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin (Nicotinic Acid)
 500 mg 92
Gluten Free Adults 18–50 Women
Report overview
Niacin (Nicotinic Acid) · 500 mg OverallScore92
A+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyC Value
Niacin-Time 500 mg provides 500 mg of nicotinic acid per serving, matching the saved cardiovascular goal. The label names the form and records a niacin-flush warning. The amount is within the stated cardiovascular range, and the cost per serving is moderate for standard niacin.
How this ingredient is rated

Active Ingredient Quality & Bioavailability100

Nicotinic acid matches the saved cardiovascular goal; no advanced precursor claim is recorded.
Niacin Form & Goal Alignment
The product names nicotinic acid for the saved cardiovascular goal.
Precursor Source Quality
It is standard niacin, with no advanced NAD+ claim in the saved facts.

Dose, Safety & Label Transparency100

The form and 500 mg amount are clear, and a niacin-flush warning is recorded.
Clarity of Chemical Form
The label explicitly identifies nicotinic acid.
Form-Specific Dosage Efficacy
The 500 mg serving is within the listed dose range for cardiovascular goals.
Flush Risk & Safety Labeling
The saved facts record a warning about niacin flush.

Value60

The serving cost is moderate for standard niacin.
Price Per Effective Serving
Its per-serving cost is in the middle range for standard nicotinic acid.
View ingredientView products
Loading alternative details
82 Performance

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best

Sustained-release nicotinic acid provides a clearly identified cardiovascular-focused amount with controlled delivery. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, high-dose niacin can still affect the liver and requires explicit safety guidance.

80 Performance

Niacin (Vitamin B3) 500 mg

Solgar

Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.

79 Performance

Niacin-Time 500 mg

Carlson

Timed-release nicotinic acid provides a transparent cardiovascular-focused dose in a long-supply format. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, controlled delivery does not remove flushing or liver-related concerns from high-dose niacin.

86 Budget

Niacinamide B-3 100 mg

Source Naturals

A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.

82 Budget

Niacin 100 mg

Nature's Way

Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. Serving cost is lower than the original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.

82 Budget

Niacin 100 mg

Bluebonnet

Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. Serving cost is lower than the original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.

80 Value

Niacin 50 mg

Carlson

A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its lower serving cost and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.

85 Value

Niacin 100 mg

Source Naturals

A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its lower serving cost and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.

80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar

Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its lower serving cost and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  8. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  9. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  10. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  11. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  12. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  13. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  14. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  15. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  16. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin